Compare Stocks: ACXP, CPHI, QNTM, and ABVC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.00 +2.0%	$0.98	$0.71 ▼ $3.33	$26.69M	0.51	126,547 shs	41,463 shs
ACXP Acurx Pharmaceuticals	$1.27 +1.6%	$1.40	$1.23 ▼ $7.98	$7.06M	-2.05	94,839 shs	40,241 shs
CPHI China Pharma	$0.87 -9.3%	$0.88	$0.38 ▼ $19.19	$37.45M	1.04	2.05 million shs	2.18 million shs
QNTM Quantum Biopharma	$2.94 -5.5%	$3.38	$2.07 ▼ $16.36	$23.78M	0.39	214,014 shs	129,496 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+2.04%	-0.99%	+3.09%	-33.77%	-69.14%
ACXP Acurx Pharmaceuticals	+1.60%	0.00%	-9.93%	-15.33%	-84.32%
CPHI China Pharma	-9.32%	+32.50%	+11.75%	+52.72%	-55.92%
QNTM Quantum Biopharma	-5.47%	-14.53%	-17.88%	-11.18%	-81.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.00 +2.0%	$0.98	$0.71 ▼ $3.33	$26.69M	0.51	126,547 shs	41,463 shs
ACXP Acurx Pharmaceuticals	$1.27 +1.6%	$1.40	$1.23 ▼ $7.98	$7.06M	-2.05	94,839 shs	40,241 shs
CPHI China Pharma	$0.87 -9.3%	$0.88	$0.38 ▼ $19.19	$37.45M	1.04	2.05 million shs	2.18 million shs
QNTM Quantum Biopharma	$2.94 -5.5%	$3.38	$2.07 ▼ $16.36	$23.78M	0.39	214,014 shs	129,496 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+2.04%	-0.99%	+3.09%	-33.77%	-69.14%
ACXP Acurx Pharmaceuticals	+1.60%	0.00%	-9.93%	-15.33%	-84.32%
CPHI China Pharma	-9.32%	+32.50%	+11.75%	+52.72%	-55.92%
QNTM Quantum Biopharma	-5.47%	-14.53%	-17.88%	-11.18%	-81.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
ACXP Acurx Pharmaceuticals	2.00	Hold	N/A	N/A
CPHI China Pharma	0.00	N/A	N/A	N/A
QNTM Quantum Biopharma	2.00	Hold	$8.00	172.11% Upside

Current Analyst Ratings Breakdown

Latest ACXP, CPHI, QNTM, and ABVC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/31/2026	QNTM Quantum Biopharma	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/21/2026	QNTM Quantum Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	ACXP Acurx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	52.33	N/A	N/A	$0.52 per share	1.92
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.07 per share	N/A
CPHI China Pharma	$3.91M	9.57	N/A	N/A	$0.70 per share	1.24
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	11/16/2026 (Estimated)
ACXP Acurx Pharmaceuticals	-$7.97M	-$2.69	N/A	N/A	N/A	N/A	-124.73%	-87.48%	11/11/2026 (Estimated)
CPHI China Pharma	-$3.08M	-$0.43	N/A	N/A	N/A	-85.56%	-63.93%	-31.42%	N/A
QNTM Quantum Biopharma	-$26.17M	-$5.49	N/A	N/A	N/A	N/A	-582.23%	-184.20%	11/6/2026 (Estimated)

Latest ACXP, CPHI, QNTM, and ABVC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	N/A	QNTM Quantum Biopharma	-$0.50	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	ACXP Acurx Pharmaceuticals	-$0.3767	-$0.53	-$0.1533	-$0.53	N/A	N/A
8/13/2026	Q2 2026	QNTM Quantum Biopharma	-$0.4116	-$0.47	-$0.0584	-$0.47	N/A	N/A
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.07	0.07
ACXP Acurx Pharmaceuticals	N/A	3.88	3.88
CPHI China Pharma	0.22	0.79	0.26
QNTM Quantum Biopharma	N/A	1.20	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ACXP Acurx Pharmaceuticals	11.53%
CPHI China Pharma	N/A
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
ACXP Acurx Pharmaceuticals	6.50%
CPHI China Pharma	6.40%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	19	26.69 million	21.62 million	Not Optionable
ACXP Acurx Pharmaceuticals	4	5.56 million	5.20 million	No Data
CPHI China Pharma	221	43.02 million	15.92 million	Not Optionable
QNTM Quantum Biopharma	7	8.09 million	7.40 million	N/A

ACXP, CPHI, QNTM, and ABVC Headlines

Recent News About These Companies

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market ...

October 8 at 9:30 PM | markets.businessinsider.com

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

October 8 at 8:00 AM | globenewswire.com

Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial

October 8 at 6:28 AM | usatoday.com

Quantum BioPharma (NASDAQ: QNTM) signs Thermo Fisher contract for Phase 2 Lucid-MS

October 8 at 2:03 AM | americanbankingnews.com

Quantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

October 7 at 12:57 PM | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

October 6, 2026 | markets.businessinsider.com

Quantum BioPharma, Thermo Fisher Partner on Phase 2 Multiple Sclerosis Trial

October 6, 2026 | finance.yahoo.com

Quantum BioPharma Advances Lucid-MS Into Phase 2 Development With Thermo Fisher Partnership

October 6, 2026 | rttnews.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

October 6, 2026 | markets.businessinsider.com

Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

October 6, 2026 | globenewswire.com

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

September 30, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing

September 25, 2026 | finance.yahoo.com

Quantum BioPharma Licensee Unbuzzd Taps New CEO Ahead of Planned Listing

September 25, 2026 | theglobeandmail.com

Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

September 25, 2026 | markets.businessinsider.com

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

September 24, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

September 23, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

September 23, 2026 | markets.businessinsider.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

September 22, 2026 | streetinsider.com

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

September 17, 2026 | markets.businessinsider.com

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

September 17, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, CPHI, QNTM, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.00 +0.02 (+2.04%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+0.70%)

As of 10/9/2026 07:30 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Acurx Pharmaceuticals NASDAQ:ACXP

$1.27 +0.02 (+1.60%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.28 +0.01 (+0.71%)

As of 10/9/2026 07:59 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

China Pharma NYSE:CPHI

$0.87 -0.09 (-9.32%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.87 0.00 (-0.29%)

As of 10/9/2026 07:59 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Quantum Biopharma NASDAQ:QNTM

$2.94 -0.17 (-5.47%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.98 +0.04 (+1.33%)

As of 10/9/2026 07:59 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACXP, CPHI, QNTM, and ABVC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACXP, CPHI, QNTM, and ABVC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACXP, CPHI, QNTM, and ABVC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, CPHI, QNTM, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Acurx Pharmaceuticals NASDAQ:ACXP

China Pharma NYSE:CPHI

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACXP, CPHI, QNTM, and ABVC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACXP, CPHI, QNTM, and ABVC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACXP, CPHI, QNTM, and ABVC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, CPHI, QNTM, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Acurx Pharmaceuticals NASDAQ:ACXP

China Pharma NYSE:CPHI

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools